Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Short Interest Update

Fidelity Disruptive Medicine ETF (NASDAQ:FMED) was the recipient of a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 100 shares, a drop of 88.9% from the February 28th total of 900 shares. Based on an average daily volume of 5,700 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the company’s stock are short sold.

Institutional Trading of Fidelity Disruptive Medicine ETF

A hedge fund recently raised its stake in Fidelity Disruptive Medicine ETF stock. Wealth Enhancement Advisory Services LLC grew its position in Fidelity Disruptive Medicine ETF (NASDAQ:FMED) by 8.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 583,615 shares of the company’s stock after purchasing an additional 43,788 shares during the quarter. Wealth Enhancement Advisory Services LLC owned approximately 27.79% of Fidelity Disruptive Medicine ETF worth $14,392,000 at the end of the most recent reporting period.

Fidelity Disruptive Medicine ETF Stock Down 1.4 %

NASDAQ FMED traded down $0.34 during trading hours on Thursday, hitting $24.32. 2,260 shares of the company were exchanged, compared to its average volume of 5,421. The company has a 50 day moving average of $25.37 and a two-hundred day moving average of $25.62. The firm has a market cap of $51.08 million, a price-to-earnings ratio of 42.35 and a beta of 0.94. Fidelity Disruptive Medicine ETF has a 52-week low of $23.32 and a 52-week high of $26.79.

About Fidelity Disruptive Medicine ETF

The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.